Among these, pralsetinib—a highly selective RET inhibitor with good brain penetration—demonstrated strong anti-proliferative activity against T98G cells and against other TMZ-resistant glioma cells that do not express RET, and against the TMZ-sensitive A172 cell line, which exhibits high RET expression (Figures 3A–C). The gene discussed is RET; the disease is glioma.